Case Studies Resources
Browse our full library of articles, whitepapers, and case studies.
26 resources
Three Facilities, Three FDA Actions, Five Architectural Gaps: How AI Agents Address Cipla's Regulatory Exposure
Between 2023 and 2026, three Cipla facilities — Pithampur, Raigad, and Pharmathen Greece — received FDA enforcement actions documenting the same five systemic failures: complaint investigation, CAPA effectiveness, electronic data review, contamination control, and QC oversight. LeucineOS AI agents map directly to each gap.
35% OOS Invalidations, Zero Scientific Justification: Lessons from Aurobindo Pharma's FDA 483
A February 2026 FDA 483 at Aurobindo Pharma's Unit-III found 35% of OOS invalidations in the QC Chemistry lab — with 57% blamed on analyst error and 18% on equipment, none supported by adequate scientific justification. Batches shipped to the US after unresolved Grade A maintenance interventions.
Equipment Swapped, Cleaning Not Revalidated, OOS Dissolved Away: Lessons from Dr. Reddy's FDA 483
A December 2025 FDA 483 at Dr. Reddy's FTO-SEZ facility in Srikakulam found cleaning validation not performed after equipment replacement, OOS dissolution results invalidated despite contradictory evidence, and process qualification gaps — all traceable to a single uncontrolled equipment change eighteen months earlier.
Flaking Caulk, Unmonitored Drains, 'Clean' Equipment with Residue: Lessons from Shilpa Medicare's FDA 483
A November 2025 FDA 483 at Shilpa Medicare found aseptic equipment with non-cleanable surfaces, drains never monitored for microbial growth, caulk-like material flaking inside filling machines, and equipment tagged as 'clean' with residue above acceptance limits.
Seven Contaminated Vials, Five Species, Zero Specific Root Causes: Lessons from Pharmathen's FDA 483
A November 2025 FDA 483 at Pharmathen International found seven contaminated media fill vials carrying Staphylococcus, Micrococcus, Kocuria, Acinetobacter, and Bacillus — all human-source microorganisms. The root cause was attributed to 'poor aseptic behavior' without identifying any specific instances.
337 Nonconformances, Reduced Retention, Zero CAPAs: Lessons from Empower Pharma's FDA 483
A November 2025 FDA 483 at Empower Pharma found 337 of 963 nonconformance reports unresolved — and the firm's response to 'poor practices' by quality personnel was to reduce record retention timelines rather than initiate corrective action.
15 Complaints, 12 Uninvestigated, One Expired Quality Agreement: Lessons from Ubi Pharma's FDA 483
An October 2025 FDA 483 at Ubi Pharma found 15 market complaints for underfill and empty vials — only 3 investigated, none with complaint samples collected, and all under an expired Quality Agreement with the US customer that had lapsed without renewal.
When Batch Records Don't Match Reality: Lessons from Hetero Labs' FDA 483
A September 2025 FDA 483 at Hetero Labs exposed batch production records that didn't match actual API yields — with unexplained drums found in an undisclosed warehouse.
When LIMS and SCADA Controls Fail: Lessons from Immacule Lifesciences' FDA 483
A September 2025 FDA 483 at Immacule Lifesciences exposed systemic failures in computerized system controls — guest accounts with analyst privileges, shared SCADA admin access, and QA unable to review audit trails.
When Cleaning Validation Misses the Worst Case: Lessons from Fareva Amboise's FDA 483
A September 2025 FDA 483 at Fareva Amboise found API residue on 'clean' equipment — 20 months after the product was last manufactured. Cleaning validation studies hadn't sampled the areas where contamination actually accumulated.
How MES Prevents FDA 483 Observations: Lessons from Dr. Reddy's Documentation Failure
A September 2025 FDA 483 observation at Dr. Reddy's exposed critical documentation gaps. Here's what went wrong and how modern MES architecture eliminates the root cause.
Environmental Monitoring Gaps in Aseptic Manufacturing: Lessons from Aurobindo Pharma's FDA 483
A September 2025 FDA 483 at Aurobindo Pharma exposed critical environmental monitoring deficiencies — unmonitored Grade A zones, inadequately validated swab methods from 2016, and missed finger dab sampling during interventions.
Crumbling Tablets, Closed Investigations: Lessons from Cohance Lifesciences' FDA 483
An August 2025 FDA 483 at Cohance Lifesciences found complaint investigations closed without follow-up, without collecting complaint samples, and without assessing impact on distributed batches — while Field Alert Reports went unfiled.
One SOP for Every System: Lessons from Lupin's FDA 483
A July 2025 FDA 483 at Lupin found a single generic SOP governing audit trail reviews across all computerized systems — with QA locked out of direct equipment access and reviewing only printed copies provided by operations.
Legacy Instruments, Zero Data Backup: Lessons from Catalent's FDA 483
A July 2025 FDA 483 at Catalent Indiana found QC instruments with disabled login features, no audit trails, no electronic data backup, and a data integrity assessment that missed critical gaps.
159 Complaints Split to Dodge the Trend, Shared Logins on Critical Systems, No Contractor Audits: Lessons from Alvotech's FDA 483
A July 2025 FDA 483 at Alvotech's biosimilar manufacturing facility in Reykjavik documented 159 product complaints split across categories to avoid triggering control limits, drug substance processed before QC release, unaudited service contractors, and shared logins on GMP-critical systems.
Altered Results, Shredded Investigations: Lessons from Natco Pharma's FDA 483
A June 2025 FDA 483 at Natco Pharma found environmental monitoring data altered from non-conforming to conforming between electronic capture and printed batch records — with operators using USB drives to transfer data.
Discarded Source Data in Media Fills: Lessons from Sun Pharma's FDA 483
A June 2025 FDA 483 at Sun Pharmaceutical found that original inspection labels were discarded after transcription into batch records — with no second-person verification and no way to confirm accuracy of the transferred data.
When Stability Trends Are Ignored Until They Fail: Lessons from Alembic's FDA 483
A May 2025 FDA 483 at Alembic Pharmaceuticals found an API impurity approximately doubling over 6 months with no investigation — because the OOT procedure only triggered on point-to-point differences.
Eight Systems, Zero Audit Trails: Lessons from Apotex's FDA 483
A May 2025 FDA 483 at Apotex documented eight distinct computerized system failures — from filling machines with no audit trails to 404 undocumented password escalations and a failed test printout found in a storage room.
Eight OOS Results, Zero Root Causes: Lessons from Glenmark's FDA 483
A February 2025 FDA 483 at Glenmark Pharmaceuticals found 8 OOS investigations for dissolution testing since April 2024 — with no specific root causes identified and batches released without re-validation.
Falsified Temperature Records, Backdated Documents, Bare Footprints in Cleaned Equipment: Lessons from Tyche Industries' FDA 483
An August 2024 FDA inspection at Tyche Industries in Kakinada found operators fabricating temperature data for equipment that was not operational, managers backdating documents during the inspection, rust residues inside cleaned equipment, and bare footprints inside production vessels — leading to Warning Letter 693081 and Import Alert 66-40.
Torn HEPA Filters, Passing Integrity Tests: Lessons from Granules India's FDA 483
A September 2024 FDA 483 at Granules India found HEPA filters severely damaged and torn — yet the facility's own integrity testing had not identified the damage. Dust collection systems showed visible build-up, and equipment tagged as 'clean' had visible residue.
Dead Instrument, No Data Backup, No Impact Assessment: Lessons from Alkem's FDA 483
A March 2024 FDA 483 at Alkem Laboratories found a QC instrument that failed during preventive maintenance — with no investigation into the impact on prior test data, no backup of electronic records, and complaint investigations closed without analytical testing.
No Audit Trails, Shared Logins, Local Storage: Lessons from Hengrui's FDA 483
A January 2024 FDA 483 at Jiangsu Hengrui Pharmaceuticals found portable NVP monitoring equipment with no audit trails, shared login credentials across shifts, HPLC data stored on unprotected local workstations, and a data integrity assessment that missed critical systems.
337 Deviations, Zero Root Causes: Lessons from Bristol Myers Squibb's FDA 483
A May 2023 FDA 483 at Bristol Myers Squibb found 337 manufacturing deviations classified as 'no impact' in just six months — with no root cause investigations, no corrective actions, and no analysis of shared causes across equipment excursions, leaks, and procedural failures.